Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Currently Amended) A compound of formula I



(I)

wherein

X is $=CR^0-$ or $=N-$;

each of R^0, R^1, R^2, R^3 and R^4 independently is hydrogen; hydroxy; C_1-C_8alkyl; C_2-C_8alkenyl; C_3-C_8cycloalkyl; C_3-C_8cycloalkyl-C_1-C_8alkyl; hydroxyC_1-C_8alkyl; C_1-C_8alkoxyC_1-C_8alkyl; hydroxyC_1-C_8alkoxyC_1-C_8alkyl; arylC_1-C_8alkyl which optionally may be substituted on the ring by hydroxy, C_1-C_8alkoxy, carboxy or C_1-C_8alkoxycarbonyl;

or R^3 and R^4 form together with the nitrogen and carbon atoms to which they are attached a 5 to 10 membered heterocyclic ring and having 1, 2 or 3 heteroatoms selected from N, O and S;

or each of R^1, R^2 and R^3, independently, is halogen; halo-C_1-C_8alkyl; C_1-C_8alkoxy; halo-C_1-C_8alkoxy; hydroxyC_1-C_8alkoxy; C_1-C_8alkoxyC_1-C_8alkoxy; aryl; arylC_1-C_8alkoxy; heteroaryl; heteroaryl-C_1-C_4alkyl; 5 to 10 membered heterocyclic ring; nitro; carboxy; C_2-C_8alkoxycarbonyl; C_2-C_8alkylcarbonyl; $-N(C_1$-C_8alkyl$)C(O)$ C_1-C_8alkyl; $-N(R^{10})R^{11}$; $-CON(R^{10})R^{11}$; $-SO_2N(R^{10})R^{11}$; or $-C_1$-C_4-alkylene-$SO_2N(R^{10})R^{11}$; wherein each of R^{10} and R^{11} independently is hydrogen; hydroxy; C_1-C_8alkyl; C_2-C_8alkenyl; C_3-C_8cycloalkyl; C_3-C_8cycloalkyl-C_1-C_8alkyl; C_1-C_8alkoxyC_1-C_8alkyl; hydroxyC_1-C_8alkoxyC_1-C_8alkyl; hydroxyC_1-C_8alkyl; (C_1-C_8alkyl)-carbonyl; arylC_1-C_8alkyl which optionally may be substituted on the ring by hydroxy, C_1-C_8alkoxy, carboxy or C_2-C_8alkoxycarbonyl; or 5 to 10 membered heterocyclic ring;

or R^1 and R^2 form together with the C-atoms to which they are attached aryl or a 5 to 10 membered heteroaryl group having one or two heteroatoms selected from N, O and S; or

~~each of~~ R^5 ~~and R^6~~ independently is hydrogen; halogen; cyano; C_1-C_8alkyl; halo-C_1-C_8alkyl; C_2-C_8alkenyl; C_2-C_8alkynyl; C_3-C_8cycloalkyl; C_3-C_8cycloalkylC_1-C_8alkyl; C_5-C_{10}arylC_1-C_8alkyl;

R^6 is hydrogen;

each of R^7, R^8 and R^9 is independently hydrogen; hydroxy; C_1-C_8alkyl; C_2-C_8alkenyl; halo-C_1-C_8alkyl; C_1-C_8alkoxy; C_3-C_8cycloalkyl; C_3-C_8cycloalkylC_1-C_8alkyl; arylC_1-C_8alkyl; -Y-R^{12} wherein Y is a direct bond or O and R^{12} is a substituted or unsubstituted 5, 6 or 7 membered heterocyclic ring having 1, 2 or 3 heteroatoms selected from N, O and S; carboxy; (C_1-C_8alkoxy)-carbonyl; -N(C_1-$_8$alkyl)-CO-$NR^{10}R^{11}$; -$CONR^{10}R^{11}$; -$N(R^{10})(R^{11})$; ~~$-SO_2N(R^{10})R^{11}$~~; R^7 and R^8 or R^8 and R^9, respectively form together with the carbon atoms to which they are attached, a 5 or 6 membered heteroaryl having 1, 2 or 3 heteroatoms selected from N, O and S; or a 5 or 6 membered carbocyclic ring;

provided that one of R^1, R^2 or R^3 is -$CON(R^{10})R^{11}$ or-$SO_2N(R^{10})R^{11}$;

in free form or salt form;

wherein

aryl represents phenyl, naphthyl or 1,2,3,4-tetrahydronaphthyl,

heteroaryl is a 5 or 6 membered aromatic heterocyclic ring, optionally condensed to 1 or 2 benzene rings and/or to a further heterocylic ring, and

wherein a heterocyclic ring is a 5 or 6 membered heterocyclic ring being saturated or unsaturated and optionally condensed to 1 or 2 benzene rings and/or to a further heterocyclic ring.

2. (Original) A process for the production of a compound of formula I according to claim 1, comprising the steps of reacting a compound of formula II



(II)

wherein R^1, R^2, R^3, R^4, R^5, R^6 and X are as defined in claim 1, and Y is a leaving group;

with a compound of formula III



(III)

wherein R^7, R^8 and R^9 are as defined in claim 1;

and recovering the resulting compound of formula I in free form or in salt form, and, where required, converting the compound of formula I obtained in free form into the desired salt form, or vice versa.

3. (Canceled)

4. (Original) A pharmaceutical composition comprising a compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable carriers or diluents therefor.

5. (Canceled)

6. (Canceled)

7. (Cancelled)

8. (Currently Amended) A method for treating ~~acute or chronic rejection of organ or tissue, atheriosclerosis, vascular occlusion, restenosis, hypertension, heart failure, chronic obstructive pulmonary disease, CNS disease,~~ breast cancer, ~~infectious disease, inflammatory disease, or autoimmune disease, in a subject in need of such treatment, which comprises~~ comprising: administering to a ~~such~~ subject in need thereof, a therapeutically effective amount of a the compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof.

9. (Cancelled)